[
  {
    "ts": null,
    "headline": "When It Comes to Healthcare, Think Big",
    "summary": "Readers weigh in on the Healthcare Roundtable, gold vs. the dollar, O’Reilly Automotive, the money manager predicament, and alts for the masses.",
    "url": "https://finnhub.io/api/news?id=9b73045470aa32956b99b461e5509eed5e090a8fa612a96195738917385fe079",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759531200,
      "headline": "When It Comes to Healthcare, Think Big",
      "id": 136980695,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Readers weigh in on the Healthcare Roundtable, gold vs. the dollar, O’Reilly Automotive, the money manager predicament, and alts for the masses.",
      "url": "https://finnhub.io/api/news?id=9b73045470aa32956b99b461e5509eed5e090a8fa612a96195738917385fe079"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know",
    "summary": "Pfizer (PFE) closed at $27.37 in the latest trading session, marking a +1.07% move from the prior day.",
    "url": "https://finnhub.io/api/news?id=43f98b3be0408a4412aacb575d3da1417ca9f6de06f13f6034d545a1cbcfd461",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759527904,
      "headline": "Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know",
      "id": 136980885,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) closed at $27.37 in the latest trading session, marking a +1.07% move from the prior day.",
      "url": "https://finnhub.io/api/news?id=43f98b3be0408a4412aacb575d3da1417ca9f6de06f13f6034d545a1cbcfd461"
    }
  },
  {
    "ts": null,
    "headline": "The Score: Pfizer, Tesla, Electronic Arts and More Stocks That Defined the Week",
    "summary": "Electronic Arts  is saying ”game over” to Wall Street in the largest leveraged buyout of all time.  The videogame maker said Monday that it would go private in a $55 billion megadeal with a group of investors including Saudi Arabia’s Public Investment Fund, private-equity firm Silver Lake and  Jared Kushner’s  investment firm Affinity Partners.  EA publishes The Sims, football game Madden NFL and FC, the soccer videogame formerly known as FIFA.",
    "url": "https://finnhub.io/api/news?id=4c20c44fa89007eea3c9879962754497f8e004382c3f4ffc95f624bd12d8bd80",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759526220,
      "headline": "The Score: Pfizer, Tesla, Electronic Arts and More Stocks That Defined the Week",
      "id": 136969976,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Electronic Arts  is saying ”game over” to Wall Street in the largest leveraged buyout of all time.  The videogame maker said Monday that it would go private in a $55 billion megadeal with a group of investors including Saudi Arabia’s Public Investment Fund, private-equity firm Silver Lake and  Jared Kushner’s  investment firm Affinity Partners.  EA publishes The Sims, football game Madden NFL and FC, the soccer videogame formerly known as FIFA.",
      "url": "https://finnhub.io/api/news?id=4c20c44fa89007eea3c9879962754497f8e004382c3f4ffc95f624bd12d8bd80"
    }
  },
  {
    "ts": null,
    "headline": "B of A Securities Maintains Pfizer (PFE) Neutral Recommendation",
    "summary": "B of A Securities Maintains Pfizer (PFE) Neutral Recommendation",
    "url": "https://finnhub.io/api/news?id=eca8b23fbe62fcc9490d7ff72269dbeb7d14bdcced582ec7a7e81a629555c65b",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759526111,
      "headline": "B of A Securities Maintains Pfizer (PFE) Neutral Recommendation",
      "id": 136967579,
      "image": "",
      "related": "PFE",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=eca8b23fbe62fcc9490d7ff72269dbeb7d14bdcced582ec7a7e81a629555c65b"
    }
  },
  {
    "ts": null,
    "headline": "US Equity Indexes Rise This Week as AI-Trade Lifts Tech, Healthcare Gains Following Pfizer Deal",
    "summary": "US equity indexes ended higher this week as a federal government shutdown in its early days failed t",
    "url": "https://finnhub.io/api/news?id=6b62ac183b5a695c26807571dc66235f3c095bc9b6f389696fe9ff0940d3a2c8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759525126,
      "headline": "US Equity Indexes Rise This Week as AI-Trade Lifts Tech, Healthcare Gains Following Pfizer Deal",
      "id": 136980575,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "US equity indexes ended higher this week as a federal government shutdown in its early days failed t",
      "url": "https://finnhub.io/api/news?id=6b62ac183b5a695c26807571dc66235f3c095bc9b6f389696fe9ff0940d3a2c8"
    }
  },
  {
    "ts": null,
    "headline": "5 Large Cap Drug Stocks: Values or Traps?",
    "summary": "Some drug stocks are cheap but is it another fake out?",
    "url": "https://finnhub.io/api/news?id=6b37ae979ad1261a96d773275c84229ccfdaabe06d40dae948855552f983204c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759524900,
      "headline": "5 Large Cap Drug Stocks: Values or Traps?",
      "id": 136980576,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Some drug stocks are cheap but is it another fake out?",
      "url": "https://finnhub.io/api/news?id=6b37ae979ad1261a96d773275c84229ccfdaabe06d40dae948855552f983204c"
    }
  },
  {
    "ts": null,
    "headline": "S&P 500 Posts Weekly Gain to Record Close, Led by Health Care Amid Pfizer Deal",
    "summary": "The Standard & Poor's 500 index rose 1.1% this week to its highest close ever, boosted by strong gai",
    "url": "https://finnhub.io/api/news?id=00e99e2e5d4a06cb6b431e3bec0ec2e702ee7023e64d9d1263cae956a327c215",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759524242,
      "headline": "S&P 500 Posts Weekly Gain to Record Close, Led by Health Care Amid Pfizer Deal",
      "id": 136980889,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The Standard & Poor's 500 index rose 1.1% this week to its highest close ever, boosted by strong gai",
      "url": "https://finnhub.io/api/news?id=00e99e2e5d4a06cb6b431e3bec0ec2e702ee7023e64d9d1263cae956a327c215"
    }
  },
  {
    "ts": null,
    "headline": "Trump administration announces MFN drug pricing deal with Pfizer",
    "summary": "The deal means Pfizer has committed to pricing current and any new medicines in all state Medicaid programs to the same prices in other developed countries.",
    "url": "https://finnhub.io/api/news?id=e7d622e9765ce6477def4cfdcfe75b7e44e2b3b829e9ad45541468fe85085550",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759509225,
      "headline": "Trump administration announces MFN drug pricing deal with Pfizer",
      "id": 136980890,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The deal means Pfizer has committed to pricing current and any new medicines in all state Medicaid programs to the same prices in other developed countries.",
      "url": "https://finnhub.io/api/news?id=e7d622e9765ce6477def4cfdcfe75b7e44e2b3b829e9ad45541468fe85085550"
    }
  },
  {
    "ts": null,
    "headline": "Pharmaceutical Stocks: Valuations And Pipelines Are Only Beginning To Be Appreciated",
    "summary": "Discover why drug stocks like LLY, NVO, AZN & PFE could outperform in 2025 amid strong healthcare trends. Click for my picks.",
    "url": "https://finnhub.io/api/news?id=39054aec8ba10e961ea96a273ddee36fc4c99bf71a99023c0844a605f6cc98ae",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759508459,
      "headline": "Pharmaceutical Stocks: Valuations And Pipelines Are Only Beginning To Be Appreciated",
      "id": 136967001,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2212761810/image_2212761810.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Discover why drug stocks like LLY, NVO, AZN & PFE could outperform in 2025 amid strong healthcare trends. Click for my picks.",
      "url": "https://finnhub.io/api/news?id=39054aec8ba10e961ea96a273ddee36fc4c99bf71a99023c0844a605f6cc98ae"
    }
  },
  {
    "ts": null,
    "headline": "Intel, Nvidia, and the ‘Visible Hand’ of Trump Capitalism",
    "summary": "Adam Smith wrote about free-market incentives nearly 250 years ago, describing them as the “invisible hand” of capitalism.",
    "url": "https://finnhub.io/api/news?id=3c2eb60c058a9ab3292e4f7e18f49799aed88e99fa6d54a3fb35ff6a8b00f7a0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759507320,
      "headline": "Intel, Nvidia, and the ‘Visible Hand’ of Trump Capitalism",
      "id": 136980620,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Adam Smith wrote about free-market incentives nearly 250 years ago, describing them as the “invisible hand” of capitalism.",
      "url": "https://finnhub.io/api/news?id=3c2eb60c058a9ab3292e4f7e18f49799aed88e99fa6d54a3fb35ff6a8b00f7a0"
    }
  },
  {
    "ts": null,
    "headline": "Detroit Carmakers Feud Over Trump’s Threatened Truck Tariffs",
    "summary": "Stellantis NV has lobbied the administration in recent days to waive or soften a possible 25% tariff that could otherwise hit medium-duty Ram pickups the company makes in Mexico, according to people familiar with the matter.  General Motors Co. and Ford Motor Co., meanwhile, have urged Trump administration officials to dismiss the request, said the people, who asked not to be identified because the discussions are private.",
    "url": "https://finnhub.io/api/news?id=1c7e3ba5a5cbe278ac22ebefa3c987ca6f658e33c039b9ed42a4fa4a5a998436",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759501745,
      "headline": "Detroit Carmakers Feud Over Trump’s Threatened Truck Tariffs",
      "id": 136965708,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Stellantis NV has lobbied the administration in recent days to waive or soften a possible 25% tariff that could otherwise hit medium-duty Ram pickups the company makes in Mexico, according to people familiar with the matter.  General Motors Co. and Ford Motor Co., meanwhile, have urged Trump administration officials to dismiss the request, said the people, who asked not to be identified because the discussions are private.",
      "url": "https://finnhub.io/api/news?id=1c7e3ba5a5cbe278ac22ebefa3c987ca6f658e33c039b9ed42a4fa4a5a998436"
    }
  },
  {
    "ts": null,
    "headline": "Palantir, AI bubble comments, pharma stocks: Trending Tickers",
    "summary": "Market Catalysts host Julie Hyman and Yahoo Finance senior reporter Allie Canal track several of the day's top trending stock tickers, including Palantir Technologies (PLTR) receiving pushback from Dutch lawmakers, commentary around an AI bubble from top executives, and pharmaceutical stocks — which includes Pfizer (PFE) — set to cap their best trading week in 16 years. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
    "url": "https://finnhub.io/api/news?id=e133b8ef1ef28dc49f1289456a1433ec675317e6785a72400f568b4c5394c051",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759506534,
      "headline": "Palantir, AI bubble comments, pharma stocks: Trending Tickers",
      "id": 136980578,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Market Catalysts host Julie Hyman and Yahoo Finance senior reporter Allie Canal track several of the day's top trending stock tickers, including Palantir Technologies (PLTR) receiving pushback from Dutch lawmakers, commentary around an AI bubble from top executives, and pharmaceutical stocks — which includes Pfizer (PFE) — set to cap their best trading week in 16 years. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
      "url": "https://finnhub.io/api/news?id=e133b8ef1ef28dc49f1289456a1433ec675317e6785a72400f568b4c5394c051"
    }
  },
  {
    "ts": null,
    "headline": "Why Shares of Eli Lilly Soared This Week",
    "summary": "Pfizer's deal with the Trump administration raised hopes that Eli Lilly would also avoid pharmaceutical tariffs.",
    "url": "https://finnhub.io/api/news?id=821e73c1ea3325030951ea371e9c82949606408e5cb4332c3c450c25972c7b7e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759502820,
      "headline": "Why Shares of Eli Lilly Soared This Week",
      "id": 136965071,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer's deal with the Trump administration raised hopes that Eli Lilly would also avoid pharmaceutical tariffs.",
      "url": "https://finnhub.io/api/news?id=821e73c1ea3325030951ea371e9c82949606408e5cb4332c3c450c25972c7b7e"
    }
  },
  {
    "ts": null,
    "headline": "BC-Most Active Stocks",
    "summary": "Elong Power Holding Ltd. 25,377,948 0.4193",
    "url": "https://finnhub.io/api/news?id=43eb8bbbba4c8b582306ffe3cf155f4dbbe31892413fbddeed04448b24002edd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759501818,
      "headline": "BC-Most Active Stocks",
      "id": 136965016,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Elong Power Holding Ltd. 25,377,948 0.4193",
      "url": "https://finnhub.io/api/news?id=43eb8bbbba4c8b582306ffe3cf155f4dbbe31892413fbddeed04448b24002edd"
    }
  },
  {
    "ts": null,
    "headline": "Wells Fargo sees ‘room to run’ for Johnson & Johnson, highlights pharma upside",
    "summary": "Investing.com -- Wells Fargo upgraded Johnson & Johnson to Overweight from Equal Weight in a note on Friday, citing attractive valuation and greater confidence in the company’s pharmaceutical growth outlook.",
    "url": "https://finnhub.io/api/news?id=51274e954c04d9e4e239d461457f22e5947f1e1a35bb0cb700647331f0cc2c69",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759500984,
      "headline": "Wells Fargo sees ‘room to run’ for Johnson & Johnson, highlights pharma upside",
      "id": 136965078,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Investing.com -- Wells Fargo upgraded Johnson & Johnson to Overweight from Equal Weight in a note on Friday, citing attractive valuation and greater confidence in the company’s pharmaceutical growth outlook.",
      "url": "https://finnhub.io/api/news?id=51274e954c04d9e4e239d461457f22e5947f1e1a35bb0cb700647331f0cc2c69"
    }
  },
  {
    "ts": null,
    "headline": "Pharma Stocks Eye Best Week in 16 Years as Trump Overhang Eases",
    "summary": "The group’s advance was spurred by Pfizer Inc. on Tuesday when it agreed to slash some of its drug prices for Americans enrolled in the Medicaid insurance program in exchange for a three-year reprieve on import tariffs.  The New York-based company also agreed to invest $70 billion in the US as part of an agreement with President Donald Trump.  The deal was seen as another sign of easing pressures on the pharmaceutical industry since the president announced possible future tariffs on drug imports in April as well as drug-pricing reforms in May. It followed Trump’s move last week to exempt companies with US manufacturing from pharmaceutical levies in the first signal of relief for the sector.",
    "url": "https://finnhub.io/api/news?id=4ed048c0b8b53dcf134371fcbdd5cfdf7bfe39a5a8cc056485e84b9d971547e8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759498087,
      "headline": "Pharma Stocks Eye Best Week in 16 Years as Trump Overhang Eases",
      "id": 136965073,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The group’s advance was spurred by Pfizer Inc. on Tuesday when it agreed to slash some of its drug prices for Americans enrolled in the Medicaid insurance program in exchange for a three-year reprieve on import tariffs.  The New York-based company also agreed to invest $70 billion in the US as part of an agreement with President Donald Trump.  The deal was seen as another sign of easing pressures on the pharmaceutical industry since the president announced possible future tariffs on drug imports in April as well as drug-pricing reforms in May. It followed Trump’s move last week to exempt companies with US manufacturing from pharmaceutical levies in the first signal of relief for the sector.",
      "url": "https://finnhub.io/api/news?id=4ed048c0b8b53dcf134371fcbdd5cfdf7bfe39a5a8cc056485e84b9d971547e8"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (PFE) Is Up 14.7% After Landmark U.S. Drug Pricing and Tariff Exemption Deal",
    "summary": "In recent days, Pfizer announced a landmark multi-year agreement with the U.S. government, committing to substantial price reductions for select prescription drugs, price-matching provisions for new launches, and participation in the TrumpRx direct-to-consumer platform in exchange for a three-year exemption from new pharmaceutical tariffs and a US$70 billion investment in domestic research, development, and manufacturing. This agreement offers increased visibility into U.S. drug pricing...",
    "url": "https://finnhub.io/api/news?id=442825d386dd8cb2d5ca54a3a95a1c5675f500ed8e7a5acbe062e3a50a1a7b4f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759496690,
      "headline": "Pfizer (PFE) Is Up 14.7% After Landmark U.S. Drug Pricing and Tariff Exemption Deal",
      "id": 136964371,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "In recent days, Pfizer announced a landmark multi-year agreement with the U.S. government, committing to substantial price reductions for select prescription drugs, price-matching provisions for new launches, and participation in the TrumpRx direct-to-consumer platform in exchange for a three-year exemption from new pharmaceutical tariffs and a US$70 billion investment in domestic research, development, and manufacturing. This agreement offers increased visibility into U.S. drug pricing...",
      "url": "https://finnhub.io/api/news?id=442825d386dd8cb2d5ca54a3a95a1c5675f500ed8e7a5acbe062e3a50a1a7b4f"
    }
  },
  {
    "ts": null,
    "headline": "Shareholders 26% loss in Pfizer (NYSE:PFE) partly attributable to the company's decline in earnings over past three years",
    "summary": "This week we saw the Pfizer Inc. ( NYSE:PFE ) share price climb by 15%. But that cannot eclipse the...",
    "url": "https://finnhub.io/api/news?id=b5551ac3783744afc624fbed0a435f10f98f8169a9aebe2b6d15677019d0096a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759496422,
      "headline": "Shareholders 26% loss in Pfizer (NYSE:PFE) partly attributable to the company's decline in earnings over past three years",
      "id": 136964372,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "This week we saw the Pfizer Inc. ( NYSE:PFE ) share price climb by 15%. But that cannot eclipse the...",
      "url": "https://finnhub.io/api/news?id=b5551ac3783744afc624fbed0a435f10f98f8169a9aebe2b6d15677019d0096a"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie: Wins Accumulating While We Wait For Next BD Steps",
    "summary": "AbbVie's strong results, pipeline wins, and Rinvoq exclusivity boost its outlook. Read the latest analysis on ABBV stock here.",
    "url": "https://finnhub.io/api/news?id=df50562df1cd4b9c1b3c819916262a60ade92b76019fd75f8d05f4fb3a90cae6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759489533,
      "headline": "AbbVie: Wins Accumulating While We Wait For Next BD Steps",
      "id": 136964952,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/912015590/image_912015590.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "AbbVie's strong results, pipeline wins, and Rinvoq exclusivity boost its outlook. Read the latest analysis on ABBV stock here.",
      "url": "https://finnhub.io/api/news?id=df50562df1cd4b9c1b3c819916262a60ade92b76019fd75f8d05f4fb3a90cae6"
    }
  },
  {
    "ts": null,
    "headline": "Cantor Fitzgerald Maintains a Hold on Pfizer (PFE)",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the best medical stocks to buy now. In a report released on September 29, Carter Gould from Cantor Fitzgerald maintained a Hold rating on Pfizer Inc. (NYSE:PFE) and set a price target of $24.00. In other news, Pfizer Inc. (NYSE:PFE) announced on September 30 the signing of a historic […]",
    "url": "https://finnhub.io/api/news?id=be366dcf6921afb5ee7fb1a9ff38b68b96fb09c6cf98e5ac1603a7e16528b3dd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759487277,
      "headline": "Cantor Fitzgerald Maintains a Hold on Pfizer (PFE)",
      "id": 136963247,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) is one of the best medical stocks to buy now. In a report released on September 29, Carter Gould from Cantor Fitzgerald maintained a Hold rating on Pfizer Inc. (NYSE:PFE) and set a price target of $24.00. In other news, Pfizer Inc. (NYSE:PFE) announced on September 30 the signing of a historic […]",
      "url": "https://finnhub.io/api/news?id=be366dcf6921afb5ee7fb1a9ff38b68b96fb09c6cf98e5ac1603a7e16528b3dd"
    }
  },
  {
    "ts": null,
    "headline": "Novartis: Superstars Entresto And Kisqali Fuel Market Outperformance",
    "summary": "Novartis shines with oncology growth, strong buybacks, and a $1.4B heart drug acquisition, defying headwinds like Entresto generics. Read why NVS stock is a buy.",
    "url": "https://finnhub.io/api/news?id=19544720167cb57ffae0079873d350c27432d55c7a1bc442759b979b242ebbe6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759481800,
      "headline": "Novartis: Superstars Entresto And Kisqali Fuel Market Outperformance",
      "id": 136964031,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1304608112/image_1304608112.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Novartis shines with oncology growth, strong buybacks, and a $1.4B heart drug acquisition, defying headwinds like Entresto generics. Read why NVS stock is a buy.",
      "url": "https://finnhub.io/api/news?id=19544720167cb57ffae0079873d350c27432d55c7a1bc442759b979b242ebbe6"
    }
  },
  {
    "ts": null,
    "headline": "3 Way-Too-Early Predictions For 2026",
    "summary": "Markets continue to advance despite continuing concerns around valuations, inflation, and the deteriorating jobs market. Read what investors need to know.",
    "url": "https://finnhub.io/api/news?id=2dd033855c21ace7dab4046d42fb6b4feb0d6bed732f97599bc4aa7fff222f45",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759479844,
      "headline": "3 Way-Too-Early Predictions For 2026",
      "id": 136963880,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2201849225/image_2201849225.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Markets continue to advance despite continuing concerns around valuations, inflation, and the deteriorating jobs market. Read what investors need to know.",
      "url": "https://finnhub.io/api/news?id=2dd033855c21ace7dab4046d42fb6b4feb0d6bed732f97599bc4aa7fff222f45"
    }
  },
  {
    "ts": null,
    "headline": "These 3 Stocks Pay More Than 6%. Are Their Dividend Yields Too Good to Be True?",
    "summary": "Dividend stocks can be great income-producing investments, but chasing high yields can sometimes leave you exposed to considerable risk.",
    "url": "https://finnhub.io/api/news?id=18be2dc89a776393e0cf3ee1d3c204144245c1a3832934330fd1ec1fa79bdc20",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759479600,
      "headline": "These 3 Stocks Pay More Than 6%. Are Their Dividend Yields Too Good to Be True?",
      "id": 136963223,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Dividend stocks can be great income-producing investments, but chasing high yields can sometimes leave you exposed to considerable risk.",
      "url": "https://finnhub.io/api/news?id=18be2dc89a776393e0cf3ee1d3c204144245c1a3832934330fd1ec1fa79bdc20"
    }
  },
  {
    "ts": null,
    "headline": "2 Reliable Dividend Stocks With Yields Above 6% That You Can Buy With $100 in October",
    "summary": "You don't need to be rich to put your money to work on Wall Street.",
    "url": "https://finnhub.io/api/news?id=701c51f3502d8da329976ad3ebd320d1aa7a47a8ddcd85d6cc703a7295c93aeb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759477680,
      "headline": "2 Reliable Dividend Stocks With Yields Above 6% That You Can Buy With $100 in October",
      "id": 136963249,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "You don't need to be rich to put your money to work on Wall Street.",
      "url": "https://finnhub.io/api/news?id=701c51f3502d8da329976ad3ebd320d1aa7a47a8ddcd85d6cc703a7295c93aeb"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Just Made a Landmark Drug Pricing Agreement with President Donald Trump. Is the Stock a Buy?",
    "summary": "The pharma giant just eliminated two big risks.",
    "url": "https://finnhub.io/api/news?id=e8cc92468bbcaa1dc266fddd8c77cd383ccc25e9d7a63cfd42cd8b91996a81a5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759475700,
      "headline": "Pfizer Just Made a Landmark Drug Pricing Agreement with President Donald Trump. Is the Stock a Buy?",
      "id": 136962267,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The pharma giant just eliminated two big risks.",
      "url": "https://finnhub.io/api/news?id=e8cc92468bbcaa1dc266fddd8c77cd383ccc25e9d7a63cfd42cd8b91996a81a5"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer’s Drug-Price Deal With Trump Followed Months of Deadlock",
    "summary": "The post, however, played a critical role in cementing a deal with one of the world’s largest pharmaceutical companies, Pfizer Inc., according to senior officials from the White House and the Centers for Medicare and Medicaid Services who requested anonymity to discuss the inner workings of the process.  For months, Pfizer and the White House had been deadlocked in their negotiations over how to address one of President Trump’s most critical issues: lowering US drug prices.",
    "url": "https://finnhub.io/api/news?id=4d1c7cfc5cd19212043a831463c038f2561f05103374276a8361b14d44fbc704",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759457507,
      "headline": "Pfizer’s Drug-Price Deal With Trump Followed Months of Deadlock",
      "id": 136962268,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The post, however, played a critical role in cementing a deal with one of the world’s largest pharmaceutical companies, Pfizer Inc., according to senior officials from the White House and the Centers for Medicare and Medicaid Services who requested anonymity to discuss the inner workings of the process.  For months, Pfizer and the White House had been deadlocked in their negotiations over how to address one of President Trump’s most critical issues: lowering US drug prices.",
      "url": "https://finnhub.io/api/news?id=4d1c7cfc5cd19212043a831463c038f2561f05103374276a8361b14d44fbc704"
    }
  },
  {
    "ts": null,
    "headline": "Inside Pfizer’s Drug-Pricing Deal With the Trump Administration",
    "summary": "Down-to-the wire team negotiations capped a long dance between President Trump and CEO Albert Bourla.",
    "url": "https://finnhub.io/api/news?id=75856322c44072b1da6df8e370fc2b58ff28b455b0c6b0a5571b829a61147f67",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759455960,
      "headline": "Inside Pfizer’s Drug-Pricing Deal With the Trump Administration",
      "id": 136960222,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Down-to-the wire team negotiations capped a long dance between President Trump and CEO Albert Bourla.",
      "url": "https://finnhub.io/api/news?id=75856322c44072b1da6df8e370fc2b58ff28b455b0c6b0a5571b829a61147f67"
    }
  }
]